In vitro activity of cefiderocol against nosocomial Acinetobacter baumannii
Microbiology Spectrum · 2025
DOI: 10.1128/spectrum.00844-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Barbara Ymaña und 20 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos - "One Health", Universidad Científica del Sur, Lima, Peru. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Cephalosporins, Acinetobacter Infections. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Cientifica del Sur, Shionogi, CYTED Ciencia y Tecnología para el Desarrollo.
Abstract (Originalsprache)
The emergence and spread of third-/fourth-generation cephalosporin and/or carbapenem-resistant Acinetobacter baumannii have become a significant global public health concern, making new treatment alternatives necessary. Thus, the present study aimed to assess in vitro cefiderocol activity against clinical isolates of A. baumannii and analyze their relationship with extended-spectrum β-lactamases (ESBLs) and carbapenemases. Ninety-five A. baumannii clinical isolates were included in the study. Susceptibility to 12 antimicrobial agents was established by automated methods and/or disk diffusion, while that of colistin was determined following microdilution and that of cefiderocol by microdilution using iron-depleted broth. The presence of bla CTX-M , bla PER , bla VEB , bla GES , bla VIM , bla IMP , bla IMI , bla KPC , bla NDM , bla OXA-23G , bla OXA-24G , bla OXA-48G , and bla OXA-58G was established by PCR. The results showed extremely high levels of resistance (>80%) to all the tested antibacterial agents except colistin (11.6%) and cefiderocol (Clinical and Laboratory Standards Institute [CLSI]: 0%; US Food and Drug Administration [FDA]: 1.1%). Following FDA criteria, 22.1% of isolates were intermediate to cefiderocol, with 68.4% of isolates surpassing the European Committee on Antimicrobial Susceptibility Testing epidemiological cut off. Seven colistin-resistant isolates were only susceptible to cefiderocol following CLSI breakpoints, four of them qualifying as cefiderocol-intermediate following FDA breakpoints. No association between the presence of ESBLs or carbapenemases and cefiderocol minimum inhibitory concentration levels was observed. The present results show the potential utility of cefiderocol in the treatment of A. baumannii infections, highlighting the need for judicious use and continuous surveillance to prevent the emergence of cefiderocol-resistant A. baumannii clones. IMPORTANCE Antibiotic resistance is a silent pandemic challenging the treatment of infectious diseases worldwide, but also other medical practices, as, for instance, organ transplantation procedures. In Peru, current levels of antimicrobial resistance are worrisome. In this scenario, we have determined the in vitro activity of cefiderocol against a series of Acinetobacter baumannii exhibiting high levels of resistance to commonly used antibiotics. This activity is independent of the presence of the most common extended-spectrum beta-lactamases or carbapenemases. Obtained results showed the potential of cefiderocol to become an alternative for the treatment of this type of microorganism, but the high number of isolates bordering the considered breakpoint, despite the lack of use of cefiderocol in the country, also shows the need for a prudent use of this antibiotic to maximize its utility while minimizing the selection of resistant isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos - "One Health", Universidad Científica del Sur, Lima, Peru.
- Servicio de Análisis Clínicos, Laboratorio de Microbiología, Hospital Universitario San Pedro, Logroño, Spain.
- Servicio de Patología Clínica área Microbiología, Hospital María Auxiliadora, Lima, Peru.
- Instituto Nacional Materno Perinatal, Lima, Peru.
- Servicio de Microbiología y Biología Molecular, Laboratorios AUNA, Lima, Peru.
- Servicio de Microbiología, Hospital María Auxiliadora, Lima, Peru.
ORCID-Profile: Beatriz Rojo-Bezares, Yolanda Sáenz, Maria J Pons, Joaquim Ruiz
Förderung
- Universidad Cientifica del Sur
- Shionogi
- CYTED Ciencia y Tecnología para el Desarrollo
- Programa Nacional de Investigación Científica y Estudios Avanzados
Zitieren
APA
Ymaña, B., Egoávil-Espejo, R., Huerto-Huánuco, R., Oporto-Llerena, R., Alonso, C. A., Castillo, A. K., Palomino-Kobayashi, L. A., Valera-Krumdieck, C., Soza, G., Ortiz-Gomez, T., Gonzales, P., López, M., Salvador-Luján, G., Rojo-Bezares, B., Casapia, M., Toledano, P., Pinto, J., Chirinos, M. R., Sáenz, Y., …, & Ruiz, J. (2025). In vitro activity of cefiderocol against nosocomial Acinetobacter baumannii. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00844-25
Vancouver
Ymaña B, Egoávil-Espejo R, Huerto-Huánuco R, Oporto-Llerena R, Alonso CA, Castillo AK, et al. In vitro activity of cefiderocol against nosocomial Acinetobacter baumannii. Microbiology Spectrum. 2025. doi:10.1128/spectrum.00844-25
BibTeX
@article{Ymaa2025,
author = {Ymaña, Barbara and Egoávil-Espejo, Rocío and Huerto-Huánuco, Rosario and Oporto-Llerena, Rosario and Alonso, Carla A and Castillo, Angie K and Palomino-Kobayashi, Luciano A and Valera-Krumdieck, Carmen and Soza, Gabriela and Ortiz-Gomez, Tamin and Gonzales, Patricia and López, María and Salvador-Luján, Gina and Rojo-Bezares, Beatriz and Casapia, Martin and Toledano, Paula and Pinto, Joseph and Chirinos, Maria Ramos and Sáenz, Yolanda and Pons, Maria J and Ruiz, Joaquim},
title = {In vitro activity of cefiderocol against nosocomial Acinetobacter baumannii},
journal = {Microbiology Spectrum},
year = {2025},
doi = {10.1128/spectrum.00844-25}
}
EUVIMED